This article is more than 5 years old. Information may no longer be current.

Combination glaucoma product granted ‘positive opinion’

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — A combination drug for the treatment of glaucoma has been recommended for approval by the Committee for Medicinal Products for Human Use in the European Union, according to a press release.

Ganfort (bimatoprost/timolol ophthalmic solution), Allergan’s combination of Lumigan and timolol, is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

The committee opinion usually serves as basis for full EU approval, according to Allergan. According to the release, the company expects approval some time during the second quarter.